Chemotherapy News and Research

Latest Chemotherapy News and Research

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.

17 Dec 2013

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013

Scientists continue work to end chemotherapy pain

With this year's $600,000 grant from the Leukemia & Lymphoma Society and $1.5 million grant from the NIH, a Saint Louis University investigator is continuing her work to end chemotherapy pain. Noted pain researcher Daniela Salvemini, Ph.D., is using the funding to capitalize on her recent finding published in Pain, a breakthrough that helps scientists understand a molecular pathway by which pain occurs with certain anti-cancer drugs.

17 Dec 2013

Chest wall resection effective for recurrent mesothelioma

Salvage chest wall resection could lengthen survival in patients with isolated chest wall recurrence of malignant pleural mesothelioma, research indicates.

16 Dec 2013

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown.

16 Dec 2013

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

Glioblastoma multiforme patients treated with experimental vaccine show improved survival

Patients with recurrent glioblastoma multiforme treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro-Oncology and accompanied by an editorial highlighting the importance of the trial.

16 Dec 2013

Experimental drug that targets macrophages decreases cancer's growth

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology annual meeting in New Orleans.

16 Dec 2013

OncoSec Medical reports positive interim data from OMS-I100 Phase 2 trial for metastatic melanoma

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced positive interim data from its ongoing Phase 2 trial of OMS-I100 in the treatment of metastatic melanoma. The results were presented by principal investigator Adil Daud, MD, at the Advances in Cancer Immunotherapy meeting at the University of California San Francisco.

16 Dec 2013

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma, the most common type of liver cancer.

16 Dec 2013

Switching chemotherapy does not improve survival in metastatic breast cancer patients with CTCs

For women with metastatic breast cancer who had elevated amounts of circulating tumor cells (CTCs) in their blood after a first line of chemotherapy, switching immediately to a different chemotherapy did not improve overall survival or time to progression, according to the results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Study could lead towards a personalised medicine for chemoresistant lymphomata

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.

16 Dec 2013

New technologies unveiled to provide expert care and streamline the process of treating breast cancer

Breast cancer patients are moms, wives, and caretakers. They are teachers, nurses, physicians and heads of industry. Today, more than ever before, women are delicately balancing the various roles of their lives. A breast cancer diagnosis and the treatment that follows is yet another challenge that unfortunately many women need to accommodate in their already busy schedules. That's why Jersey Shore University Medical Center, Ocean Medical Center and Riverview Medical Center offer technologies that provide expert care and streamline the process of treating breast cancer.

14 Dec 2013

Analysis provides first empirical evidence on how shared savings ACO model affect quality of care

Approximately 10 percent of Medicare spending is for cancer care, and Medicare spending is nearly four times higher for beneficiaries with cancer than in those without the disease. Little is known about how to curb spending growth while maintaining or improving quality of care for these high-risk, high-cost patients.

14 Dec 2013

UTHealth professor wins Founders' Laurel Award for exceptional service in the field of medical education

Arthur L. Day, M.D., professor of neurosurgery at The University of Texas Health Science Center at Houston and a neurosurgeon at the Mischer Neuroscience Institute at Memorial Hermann-Texas Medical Center, has received one of the top honors awarded by the Congress of Neurological Surgeons.

14 Dec 2013

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

14 Dec 2013

Researchers test promising new breast cancer drugs

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.

14 Dec 2013

UTHealth Medical School professor recognized for excellence in sarcoma treatment

Rex Marco, M.D., professor in the Department of Orthopaedic Surgery at The University of Texas Health Science Center at Houston Medical School, is the recipient of an award recognizing excellence in the treatment of a type of cancer called sarcoma.

14 Dec 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Scientists continue work to end chemotherapy pain

Chest wall resection effective for recurrent mesothelioma

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Glioblastoma multiforme patients treated with experimental vaccine show improved survival

Experimental drug that targets macrophages decreases cancer's growth

OncoSec Medical reports positive interim data from OMS-I100 Phase 2 trial for metastatic melanoma

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Switching chemotherapy does not improve survival in metastatic breast cancer patients with CTCs

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Study could lead towards a personalised medicine for chemoresistant lymphomata

New technologies unveiled to provide expert care and streamline the process of treating breast cancer

Analysis provides first empirical evidence on how shared savings ACO model affect quality of care

UTHealth professor wins Founders' Laurel Award for exceptional service in the field of medical education

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Researchers test promising new breast cancer drugs

UTHealth Medical School professor recognized for excellence in sarcoma treatment

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in